IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
igc pharma 2024年第四季度GAAP每股收益爲$(0.04)，銷售額爲295,000美元，超過了193,000美元的估計
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.04) per share. The company reported quarterly sales of $295.000 thousand which beat the analyst consensus estimate of $193.000 thousand by 52.85 percent. This is a 77.71 percent increase over sales of $166.000 thousand the same period last year.
IGC Pharma（美國證券交易所股票代碼：IGC）公佈的季度虧損爲每股0.04美元。該公司公佈的季度銷售額爲29.5萬美元，比分析師普遍預期的19.3萬美元高出52.85％。這比去年同期的16.6萬美元的銷售額增長了77.71％。